#NewAseBioMember | “AseBio is the meeting point and the voice of the biotech sector in Spain”
Meet ELE Biotech, our new member. We spoke with Laura Vallés Saiz and Elena Calvo Cantero, CEO and co-founder, and COO and also co-founder, respectively.
AseBio. What does your company's work bring to the table and what is its strength?
Laura Vallés y Elena Calvo. At ELE Biotech, we work to transform how neurodegenerative diseases are detected and understood by bringing early detection of dementia risk into an accessible, scalable, evidence-based setting. Our goal is to move from a reactive model to a preventive one, enabling action before symptoms appear and generating real impact for patients, healthcare systems, and society.
Our main strength is the scientific robustness of our approach and its clear translational focus. We start from a proprietary biomarker and work with a rigorous approach to translate research into the clinical setting in a safe and scalable way.
In addition, we combine molecular biology, clinical data, and predictive technology with a collaborative vision alongside the healthcare and scientific ecosystem, which enables us to develop solutions with high potential impact in the prevention of neurodegenerative diseases.
AseBio. What is AseBio for you?
Laura Vallés y Elena Calvo. For us, AseBio is the meeting point and the voice of the biotech sector in Spain: it connects industry, science, and the healthcare system, fosters collaboration, and helps innovation reach patients sooner.
AseBio. When did you first hear about AseBio?
Laura Vallés y Elena Calvo. We first came across AseBio when we began engaging with the biotech ecosystem, attending events and closely following the sector’s activity.
AseBio. What do you expect from being part of an association like AseBio?
Laura Vallés y Elena Calvo. We hope to build collaborations (industry, research centres, and hospitals), increase our visibility, and learn from best practices in the sector. We also want to stay up to date on regulation, funding, and internationalisation opportunities relevant for startups.
AseBio. What is the biggest challenge facing the biotech sector or your company?
Laura Vallés y Elena Calvo. The biggest challenge is managing the long development timelines inherent to the sector without being able to commercialise in the early stages, and the associated costs required to progress through R&D, validation, and regulatory preparation until reaching the market.